EC Number   |
Application |
Reference |
|---|
   3.1.6.12 | diagnostics |
altered ARSB immunostaining and reduced activity may be useful indicators of malignant transformation in human colonic tissue |
715789 |
| 3.1.6.12 | medicine |
administration of recombinant enzyme as 2- and 4-h intravenous infusions using a feline model of mucopolysaccharidosis VI does not lead to significant differences in clinical outcomes such as urinary glycosaminoglycan excretion, tissue glycosaminoglycan storage, tissue galsulfase activity, and beta-glucuronidase but all are significantly different to control animals |
751571 |
| 3.1.6.12 | medicine |
application of a combined assay for defects in iduronate-2-sulfatase (ID2S) leading to mucopolysaccharidosis II, and N-acetylgalactosamine-6-sulfatase (GALN) and N-acetylgalactosamine-4-sulfatase (ARSB) defects related to mucopolysaccharidosis IVA and MPS VI, respectively. The average enzyme activities of ID2S, GALN, and ARSB in random neonates are 19.6, 1.7, and 13.4 micromol/h/l, respectively. The average enzyme activities of ID2S, GALN, and ARSB in disease-affected individuals are 0.5, 0.3, and 0.3 micromol/h/l, respectively |
751576 |
| 3.1.6.12 | medicine |
application of recombinant enzyme may give improvement in mucopolysaccheridosis VI |
681957 |
| 3.1.6.12 | medicine |
ARSB is reduced in cystic fibrosis cells and increases when defective cystic fibrosis transmembrane conductance regulator CFTR is repaired. The CFTR potentiator VRT-532 increases ARSB activity and expression to the level in normal bronchial epithelial cells. Concomitantly, total sulfated glycosaminoglycans and chondroitin 4-sulfate decline, secreted interleukin IL-8 increases, secreted IL-6 declines, and neutrophil chemotaxis to the spent media obtained from the potentiator-treated cystic fibrosis cells increases |
752147 |
| 3.1.6.12 | medicine |
deficiency in Maroteaux-Lamy syndrome, mucopolysaccharidosis type IV |
135542, 135548, 135557, 135560 |
| 3.1.6.12 | medicine |
deficiency of arylsulfatase B causes mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome) |
691877 |
| 3.1.6.12 | medicine |
enzyme replacement in MPS IV feline fibroblast |
135556, 135563 |
| 3.1.6.12 | medicine |
in human prostate cancer tissues, the N-acetylgalactosamine-4-sulfatase ARSB activity is reduced and the galactosamine-N-acetyl-6-sulfatase GALNS activity is increased, compared to normal prostate tissue |
751772 |
| 3.1.6.12 | medicine |
in prostatic malignancy, activity of arylsulfatase B declines. Arylsulfatase B may be useful as a biomarker of prostate cancer. In 82% of paired cases, the biochemical recurrences show lower arylsulfatase B immunostaining at the time of prostatectomy. Arylsulfatase B immunostaining is inversely associated with Gleason scores for epithelial and stromal compartments separately and in combination. Arylsulfatase B activity is significantly less in the malignant compared to normal tissue. In association with reduced arylsulfatase B activity, total sulfated glycosaminoglycans and chondroitin-4-sulfate content are increased in the malignant prostatic tissue, and the chondroitin-4-sulfate containing matrix proteoglycan versican is also increased |
730856 |
